Ligustrazine Attenuates Hyperhomocysteinemia-induced Alzheimer-like Pathologies in Rats

Abstract

Ligustrazine, an alkaloid extracted from the traditional Chinese herbal medicine Ligusticum Chuanxiong Hort, has been clinically applied to treat the cerebrovascular diseases. Hyperhomocysteinemia (Hhcy) is an independent risk factor for Alzheimer’s disease (AD). Memory deficits can be caused by Hhcy via pathologies of AD-like tau and amyloid-β (Aβ) in the hippocampus. Here, we investigated whether homocysteine (Hcy) can induce AD-like pathologies and the effects of ligustrazine on these pathologies. The Hcy rat model was constructed by 14-day Hcy injection via vena caudalis, and rats were treated with daily intragastric administration of ligustrazine at the same time. We found that the pathologies of tau and Aβ were induced by Hcy in the hippocampus, while the Hcy-induced tau hyperphosphorylation and Aβ accumulation could be markedly attenuated by simultaneous ligustrazine treatment. Our data demonstrate that ligustrazine may be used as a promising neuroprotective agent to treat the Hcy-induced AD-like pathologies.

Keywords

Alzheimer’s disease / ligustrazine / hyperhomocysteinemia / phosphorylated tau / cognitive impairment

References

[1] BrookmeyerR, JohnsonE, Ziegler-GrahamK, et al.. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement, 2007, 3(3): 186-191

[2] ArmstrongRA. Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol, 2006, 44(1): 1-11

[3] PorteliusE, ZetterbergH, AndreassonU, et al.. An Alzheimer’s disease-specific β-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett, 2006, 409(3): 215-219

[4] MendesD, OliveiraMM, MoreiraPI, et al.. Beneficial effects of white wine polyphenols-enriched diet on Alzheimer’s disease-like pathology. J Nutr Biochem, 2018, 55: 165-177

[5] SmithAD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine?. Food Nutr Bull, 2008, 29(2 Suppl): S143-S172

[6] RefsumH, SmithAD, UelandPM, et al.. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem, 2004, 50(1): 3-32

[7] SeshadriS, BeiserA, SelhubJ, et al.. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med, 2002, 346(7): 476-483

[8] ClarkeR, SmithAD, JobstKA, et al.. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol, 1998, 55(11): 1449-1455

[9] HooshmandB, SolomonA, KareholtI, et al.. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology, 2010, 75(16): 1408-1414

[10] RavagliaG, FortiP, MaioliF, et al.. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr, 2005, 82(3): 636-643

[11] SunBL, LiWW, ZhuC, et al.. Clinical research on Alzheimer’s disease: progress and perspectives. Neurosci Bull, 2018, 34(6): 1111-1118

[12] XuK, WangPL, XuX, et al.. An overview on structural modifications of ligustrazine and iological evaluation of its synthetic derivatives. Res Chem Intermediat, 2015, 41: 1385-1411

[13] ZhangC, WangSZ, ZuoPP, et al.. Protective effect of tetramethylpyrazine on learning and memory function in D-galactose-lesioned mice. Chin Med Sci J, 2004, 19(3): 180-184

[14] ChenHF, LiGN, ZhanP, et al.. Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. Eur J Med Chem, 2012, 46(11): 5609-5615

[15] ZhangT, GuJB, WuLM, et al.. Neuroprotective and axonal outgrowth-promoting effects of tetramethylpyrazine nitrone in chronic cerebral hypoperfusion rats and primary hippocampal neurons exposed to hypoxia. Neuropharmacology, 2017, 118: 137-147

[16] LuC, ZhangJ, ShiXP, et al.. Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson’s disease induced by MPTP. Int J Biol Sci, 2014, 10(4): 350-357

[17] SoEC, WongKL, HuangTC, et al.. Tetramethylpyrazine protects mice against thioacetamide-induced acute hepatotoxicity. J Biomed Sci, 2002, 9(5): 410-414

[18] ZhuXL, XiongLZ, WangQ, et al.. Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats. Neurosci Lett, 2009, 449(1): 24-27

[19] FanLH, WangKZ, ChengB, et al.. Anti-apoptotic and neuroprotective effects of tetramethylpyrazine following spinal cord ischemia in rabbits. BMC Neurosci, 2006, 7: 48

[20] ChengXR, ZhangL, HuJJ, et al.. Neuroprotective effects of tetramethylpyrazine on hydrogen peroxide-induced apoptosis in PC12 cells. Cell Biol Int, 2007, 31(5): 438-443

[21] ZhaoTF, FuYX, SunH, et al.. Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. IUBMB Life, 2018, 70(1): 60-70

[22] SinghC, LiuLF, WangJM, et al.. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTg AD and nonTg mice. Neurobiol Aging, 2012, 33(8): 1493-1506

[23] BrionJP, CouckAM, ConreurJL. Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer’s disease. Neurodegeneration, 1995, 4(1): 13-21

[24] MinthonL, HesseC, SjogrenM, et al.. The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett, 1997, 226(1): 65-67

[25] TakahashiM, TsujiokaY, YamadaT, et al.. Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain. Acta Neuropathol, 1999, 97(6): 635-641

[26] JanusC, PhinneyAL, ChishtiMA, et al.. New developments in animal models of Alzheimer’s disease. Curr Neurol Neurosci Rep, 2001, 1(5): 451-457

[27] DoodyRS, ThomasRG, FarlowM, et al.. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med, 2014, 370(4): 311-321

[28] ZhaoL, WeiM, HeM, et al.. The effects of tetramethylpyrazine on learning and memory abilities of mice with Alzheimer disease and its possible mechanism. Chin Pharmacol Bull, 2008, 24(8): 1088-1092

[29] ShiJ, WangYM, LuoGA. Ligustrazine phosphate ethosomes for treatment of Alzheimer’s Disease, in vitro and in animal model studies. AAPS PharmSciTech, 2012, 13(2): 485-492

[30] TanF, FuWJ, ChengNF, et al.. Ligustrazine reduces blood-brain barrier permeability in a rat model of focal cerebral ischemia and reperfusion. Exp Ther Med, 2015, 9(5): 1757-1762

[31] QiCF, LiuY, ZhangJS, et al.. Effect of ligustrazine on nNOS expression and neuranagenesis in adult rats after cerebral ischemia-reperfusion injury. Nan Fang Yi Ke Da Xue Xue Bao (Chinese), 2007, 27(6): 771-774

[32] ObeidR, HerrmannW. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett, 2006, 580(13): 2994-3005